Literature DB >> 34697464

Phase IIa results for potential NAFLD therapy.

Claire Greenhill1.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 34697464     DOI： 10.1038/s41574-021-00590-2

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  1 in total

1.  ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials.

Authors:  Roberto A Calle; Neeta B Amin; Santos Carvajal-Gonzalez; Trenton T Ross; Arthur Bergman; Sudeepta Aggarwal; Collin Crowley; Anthony Rinaldi; Jessica Mancuso; Naresh Aggarwal; Veena Somayaji; Malgorzata Inglot; Theresa A Tuthill; Kou Kou; Magalie Boucher; Greg Tesz; Robert Dullea; Kendra K Bence; Albert M Kim; Jeffrey A Pfefferkorn; William P Esler
Journal:  Nat Med       Date:  2021-10-11       Impact factor: 53.440
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.